GlassScriptPhysician profile
Gregory A Lieb
NPI 1962400952
$2,878.79
in general payments reported to CMS, 2019-2025
24 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $190 · 2021: $75.10 · 2022: $395 · 2023: $492 · 2024: $353 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $424.55 | 2024-2025 | Tepezza |
| Abbvie INC. | $406.36 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $347.72 | 2019-2024 | Cequa |
| Horizon Therapeutics Plc | $340.48 | 2022-2023 | Tepezza |
| Alcon Vision LLC | $240.83 | 2022-2025 | Acrysof Iq Vivity, Argos, Constellation |
| Bausch & Lomb Americas INC. | $223.77 | 2022-2025 | Vyzulta, Scoutpro Osmolarity System, Miebo |
| Dompe US, INC. | $119.32 | 2024-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $112.08 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Aerie Pharmaceuticals, INC. | $92.54 | 2019-2021 | |
| Alcon Research LLC | $86.86 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $85.32 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.88 | 2019-2021 | |
| Optovue, INC. | $59.52 | 2019 | |
| Coopervision INC. | $47.39 | 2024 | Myday Contact Lens |
| Rayner Intraocular Lenses Limited | $31.90 | 2025 | Omidria |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.36 | 2025 | Vabysmo |
| Allergan, INC. | $29.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.46 | 2019-2020 | |
| Harrow Eye, LLC | $22.78 | 2024 | Vevye |
| Eyevance Pharmaceuticals LLC | $20.81 | 2021 | |
| Kala Pharmaceuticals, INC. | $20.11 | 2021 | |
| Rxsight INC | $17.51 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Oyster Point Pharma, INC. | $15.17 | 2022 | |
| Abb Con-Cise Optical Group LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.